C5 and paroxysmal nocturnal hemoglobinuria: Eculizumab (Soliris®, Alexion Pharmaceuticals, Inc., Boston, MA, USA), a first-in-class monoclonal antibody C5 inhibitor, was approved for the treatment of PNH based on its efficacy in two phase III clinical trials (TRIUMPH and SHEPHERD) [17,18].